Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ANIX, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Follicle Stimulating Hormone Receptor T | Ovarian Cancer | Phase 1 · NCT05316129 | Recruiting |
| Zymosan | Pathologic Stage IIA-IIIC Triple-Negative Breast C | Early Phase 1 · NCT04674306 | Completed |
| α-lactalbumin vaccine | Pathologic Stage IIA-IIIC Triple-Negative Breast C | Early Phase 1 · NCT04674306 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ANIX holds $13.9M in cash and short-term investments (as of Jul 31, 2026) and burns about $1.8M/quarter from operations, an estimated runway of 23.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 33 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ANIX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Lewis H jr Titterton Director · +50,000 options |
Insider | 1,046,003 | 3.01% | 2026-09-23 |
| Amit Kumar Chief Executive Officer, Director · +350,000 options |
Insider | 672,000 | 1.93% | 2026-09-24 |
| Arnold M Baskies Director · +25,000 options |
Insider | 140,572 | 0.40% | 2026-09-24 |
| Michael Catelani President, COO, & CFO · +175,000 options |
Insider | 50,000 | 0.14% | 2026-09-30 |
Share count 34,763,802 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANIX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →